ºê·£µå Á¦³×¸¯ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, ¼¼°è ¿¹Ãø(2023-2032³â)
Branded Generics Market - By Drug Class (Anti-hypertensive, Hormones, Antimetabolites), Application (Oncology, Cardiovascular Diseases), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacy), Global Forecast, 2023 - 2032
»óǰÄÚµå : 1368713
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2023³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,850,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,545,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,794,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå ±Ô¸ð´Â 2023-2032³â ÇöÀúÇÑ ¼ºÀå·üÀ» º¸ÀÔ´Ï´Ù.

Á¦³×¸¯ ÀǾàǰÀÇ º¸±ÞÀ» À§ÇÑ Á¤ºÎÀÇ ±¸»óÀº ½ÃÀå¿¡ ÀÚ±ØÀûÀÎ È¿°ú¸¦ °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ½ºÀ§½º Á¤ºÎ´Â 2023³â 9¿ù °Ç°­ º¸Çè Á¶·Ê, ÀÇ·á ¼­ºñ½º Á¶·Ê, ÀǾàǰ Á¶·Ê °³Á¤¾ÈÀ» ½ÂÀÎÇϰí 2024³â 1¿ù 1ÀϺÎÅÍ ½ÃÇàÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌ °³Á¤¾ÈÀº Á¦³×¸¯ ÀǾàǰÀÇ ºñ¿ë È¿À²¼ºÀ» ¿À¸®Áö³Î ÀǾàǰº¸´Ù ³ôÀÌ´Â µ¿½Ã¿¡ ´õ ºñ½Ñ ¼±ÅñÇÀ» ¼±ÅÃÇÒ °æ¿ì ȯÀÚÀÇ Àڱ⠺δã±ÝÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ Àü·«Àû ¿òÁ÷ÀÓÀº ¿¬°£ 2¾ï 5õ¸¸ ½ºÀ§½ºÇÁ¶û(¹ÌÈ­ 275¸¸ ´Þ·¯ »ó´ç)À» Àý¾àÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

Àú·ÅÇÑ Á¦³×¸¯ ÀǾàǰÀÇ »ç¿ëÀ» Àå·ÁÇÏ´Â Á¤ºÎ Á¤Ã¥Àº °æÀï ȯ°æÀ» Á¶¼ºÇϰí, Á¦¾àȸ»çµéÀÌ ºê·£µå Á¦³×¸¯ ÀǾàǰ »ý»ê¿¡ ÀÖÀ¸¸ç, ±â¼ú Çõ½ÅÀ» ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °æÀïÀº °íǰÁúÀÇ ºñ¿ë È¿À²ÀûÀÎ ºê·£µå Á¦³×¸¯ ÀǾàǰÀÇ À¯Çü¸¦ ´Ã¸®°í, ÀǾàǰ ½ÃÀåÀÇ ¼±ÅÃÀÇ ÆøÀ» ³ÐÈ÷¸ç, °¡°ÝÀ» ³·Ãç ¼ÒºñÀÚ¿¡°Ô ÀÌÀÍÀ» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù.

2032³â±îÁö ºê·£µå Á¦³×¸¯ »ê¾÷ÀÇ ¿ëµµº° »óȲÀº ¼øÈ¯±â Áúȯ ºÐ¾ß°¡ Áö¹èÀûÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ȯÀÚ¿Í ÀÇ·á Àü¹®°¡µéÀº Áß¿äÇÑ ÀǾàǰ¿¡ ´ëÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â ºê·£µå À̸§À» ¼±È£Çϸç, ÀÌ´Â ½Å·Ú¼º°ú ǰÁúÀÌ º¸ÀåµÇ±â ¶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ºê·£µå Á¦³×¸¯Àº ȯÀÚÀÇ ¼±È£µµ¿Í Çʿ信 µû¶ó ƯÁ¤ Á¦Çü°ú Åõ¿© ¹æ¹ýÀ» Á¦°øÇϱ⵵ ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä´Â ½ÉÇ÷°ü °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í È¿°úÀûÀÌ°í °ËÁõµÈ Ä¡·á¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

¿Ü¿ë ºê·£µå Á¦³×¸¯ ½ÃÀåÀº 2032³â±îÁö °Ç°­ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀÔ´Ï´Ù. ¿Ü¿ë ºê·£µå Á¦³×¸¯ ÀǾàǰÀÇ ¸ÅÃâÀº È¿´É, °æÁ¦¼º, Ä£¼÷ÇÔ µîÀ¸·Î ÀÎÇØ Áõ°¡ Ãß¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚµéÀº ÇǺΠ¹× ÇコÄɾî Á¦Ç°¿¡ ´ëÇØ Àß ¾Ë·ÁÁø ºê·£µå À̸§À» ½Å·ÚÇÏ°í ¼±È£ÇÕ´Ï´Ù. ¿Ü¿ëÁ¦ ºê·£µå Á¦³×¸¯Àº Á¾Á¾ ºê·£µå Á¦Ç°°ú µ¿µîÇÑ Ç°Áú°ú ¼º´ÉÀ» Àú·ÅÇÑ °¡°ÝÀ¸·Î Á¦°øÇÏ¿© ºñ¿ë¿¡ ¹Î°¨ÇÑ ¼ÒºñÀڵ鿡°Ô ¾îÇÊÇϰí ÀÖ½À´Ï´Ù. ÇǺΠ°Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í ½Å·ÚÇÒ ¼ö ÀÖ´Â ´ëüǰÀÇ °¡¿ë¼ºÀº ½ÃÀå¿¡¼­ Á¦³×¸¯ ÀǾàǰÀÇ Àα⠻ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ ºê·£µå Á¦³×¸¯ ÀǾàǰ »ê¾÷Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. À¯·´ ¼ÒºñÀÚµéÀº ǰÁúÀ» ¿ì¼±½ÃÇϸç, Á¦³×¸¯ ÀǾàǰÀÌ¶óµµ ºê·£µå°¡ Àß ¾Ë·ÁÁø Á¦Ç°À» ½Å·ÚÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ ÀÇ·á ½Ã½ºÅÛÀº ºñ¿ë È¿À²ÀûÀÎ Á¦³×¸¯ ÀǾàǰ »ç¿ëÀ» Àå·ÁÇϰí ÀÖÀ¸¸ç, À̴ ȯÀÚ¿Í Á¤ºÎ ¿¹»ê ¸ðµÎ¿¡ ÀÌÀÍÀ» °¡Á®´ÙÁÝ´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©µµ ºê·£µå Á¦³×¸¯ÀÇ ¼ºÀåÀ» Áö¿øÇÏ¿© Á¦¾à»ç°¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ» Á¦°øÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ È¯°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºê·£µå Á¦³×¸¯ ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ºê·£µå Á¦³×¸¯ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, 2018-2032³â

Á¦6Àå ºê·£µå Á¦³×¸¯ ½ÃÀå : ¿ëµµº°, 2018-2032³â

Á¦7Àå ºê·£µå Á¦³×¸¯ ½ÃÀå : Åõ¿© °æ·Îº°, 2018-2032³â

Á¦8Àå ºê·£µå Á¦³×¸¯ ½ÃÀå : À¯Åë ä³Îº°, 2018-2032³â

Á¦9Àå ºê·£µå Á¦³×¸¯ ½ÃÀå : Áö¿ªº°, 2018-2032³â

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Branded Generics Market size will exhibit an appreciable growth rate between 2023 and 2032. Government initiatives aimed at promoting generic products can have a stimulating effect on the market. In September 2023, the Swiss government approved changes to the Ordinance on Health Insurance, the Ordinance on Health Care Services, and the Ordinance on Medicinal Products, scheduled to be implemented on January 1, 2024. These revisions aim to make generic drugs more cost-effective compared to their brand-name counterparts while also raising patients' co-payments for selecting pricier options. This strategic move is designed to achieve annual savings of CHF 250 million, equivalent to $275 million.

By encouraging the use of more affordable generic alternatives, government policies create a competitive environment, prompting pharmaceutical companies to innovate in producing branded generic products. This competition can lead to a wider range of high-quality, cost-effective branded generics, benefiting consumers with increased choices and potentially lower prices in the pharmaceutical market.

The overall branded generics market is categorized based on drug class, application, route of administration, distribution channel, and region.

The cardiovascular disease segment could dominate the application landscape of the branded generics industry by 2032. Patients and healthcare professionals often prefer trusted brand names for critical medications, ensuring reliability and quality. Additionally, branded generics may offer specific formulations or delivery methods that cater to patient preferences and needs. This demand is further propelled by a growing awareness of cardiovascular health and a focus on effective, well-established treatments.

Topical branded generics market will demonstrate a healthy growth rate through 2032. Sales of topical branded generics are on the rise due to their effectiveness, affordability, and familiarity. Consumers trust well-known brand names for skin and healthcare products, making them a preferred choice. Topical branded generics often offer the same quality and performance as their brand-name counterparts at a lower cost, appealing to cost-conscious consumers. The increasing awareness of skin health and the availability of these trusted alternatives contribute to their growing popularity in the market.

Europe branded generics industry is experiencing robust growth due to several key factors. European consumers prioritize quality and trust established brand names for pharmaceuticals, even in generic forms. Additionally, healthcare systems in the region encourage the use of cost-effective generics, benefiting both patients and government budgets. Regulatory frameworks also support the growth of branded generics, creating a favorable environment for pharmaceutical companies to offer these trusted alternatives.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Branded Generics Industry Insights

Chapter 4 Competitive Landscape, 2022

Chapter 5 Branded Generics Market, By Drug Class, 2018 - 2032 (USD Million)

Chapter 6 Branded Generics Market, By Application, 2018 - 2032 (USD Million)

Chapter 7 Branded Generics Market, By Route of Administration, 2018 - 2032 (USD Million)

Chapter 8 Branded Generics Market, By Distribution Channel, 2018 - 2032 (USD Million)

Chapter 9 Branded Generics Market, By Region, 2018 - 2032 (USD Million)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â